Immunotherapy and emerging targets in phase 3
EASL LiverTree™, Sandrine Faivre, 210753
EASL-EASD Symposium: Testing strategies and pathways in NAFLD: Panel Discussion
EASL LiverTree™, Session Speakers, 212772
The Cardiologist perspective
EASL LiverTree™, Christopher D. Byrne, 210741
The road ahead – will novel HBV treatments enter clinics soon? Immunological therapies
EASL LiverTree™, Mala Maini, 210757
Revised 2018 WHO Guidelines for the care and treatment of persons with chronic HCV
EASL LiverTree™, Dr. Marc Bulterys & Dr. Saeed Sadiq Hamid, 214370
The General Practicionner perspective
EASL LiverTree™, Rachel Pryke, 210740
Systemic therapy: Current status and lessons learned from success and failure
EASL LiverTree™, Maria Reig, 210752
Clinicians as key partners in meeting the 2030 elimination goals
EASL LiverTree™, Rakesh Aggarwal, 210746
Stopping NUC therapy before HBsAg loss – a good idea?
EASL LiverTree™, Florian van Boemmel, 210756
Ablation and transarterial approaches. Efficacy vs benefit
EASL LiverTree™, Jens Ricke, 210751
Fighting HBV with limited resources: The global perspective
EASL LiverTree™, Maud Lemoine, 210755
EASL-EASD Symposium: Testing strategies and pathways in NAFLD: Chair
EASL LiverTree™, Laurent Castera, 210736
The Hepatologist perspective
EASL LiverTree™, Lawrence Serfaty, 210738
Monitoring progress towards the elimination of viral hepatitis
EASL LiverTree™, Yvan Hutin, 210744
Short review of unmet needs in HCC treatment
EASL LiverTree™, Jordi Bruix, 210750
Introduction: Aims and open questions in HBV management
EASL LiverTree™, Jörg Petersen, 210754
EASL-WHO symposium: Meeting the 2030 elimination goals of the WHO viral hepatitis strategy: Introduction
EASL LiverTree™, Prof. Tom Hemming Karlsen & Gottfried Hirnschall, 214368
Quantifying the Impact of Achieving the World Health Organization (WHO) Global Health Sector Strategy (GHSS) Goals for Hepatitis C in the EURO Region
EASL LiverTree™, Sarah Blanch, 206383
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the 'underwater portion of the iceberg' matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries?
EASL LiverTree™, Sarah Blach, 206385
Bile duct organogenesis using ECM micropatterning
EASL LiverTree™, Mazari-Arrighi Elsa, 206943
Comparing the prevention gains of different treatment strategies at the global, regional, and country level: a modelling study
EASL LiverTree™, Adam Trickey, 206444
Selective NDRP1 E3 ubiquitin ligase overexpression in inflammatory macrophages using functionalized carbon nanoparticles promotes fibrosis regression in cirrhotic mice
EASL LiverTree™, Pedro Melgar-Lesmes, 206894
Preliminary efficacy and safety of acetyl-CoA carboxylase (ACC) inhibitor GS-0976 in patients with compensated cirrhosis due to NASH
EASL LiverTree™, Mazen Noureddin, 207296
Development and characterization of unique Hepatitis C virus neutralizing antibodies associated with infection outcome
EASL LiverTree™, Shiri Elmedvi Baran, 207745
Interim evaluation and projected impact of the hepatitis C virus elimination program in Georgia
EASL LiverTree™, Aaron Lim, 206373
Nurse-led Clinic for Liver Cirrhotic Patients: Effects on Health Related Quality of Life
EASL LiverTree™, Maria Hjorth, 206837
Effects of a PEGylated fibroblast growth factor 21 variant on steatosis, inflammation, and fibrosis in a mouse model of non-alcoholic steatohepatitis
EASL LiverTree™, Bradley Zinker, 206886
A pan-genotype HCV T cell vaccine, in a simian adenovirus vector, to target T cell epitopes conserved across multiple HCV genotypes
EASL LiverTree™, Timothy Donnison, 207749
Scale-up of the national HCV screening and treatment program in Indonesia: data from Jakarta, West Java and Central Java
EASL LiverTree™, Jilian Sacks, 206400
Human amnion epithelial cells reduce liver fibrosis via effects on macrophages phenotype and liver progenitor cells in murine liver injury
EASL LiverTree™, Majid Alhomrani, 206902
Effet of bariatric surgery in biopsy-proven NASH patients after 5 years
EASL LiverTree™, Guillaume Lassailly, 207293
Seeking genetic determinants of resistance to hepatitis C virus infection in a highly resistant cohort
EASL LiverTree™, Daniel Felmlee, 207669
The impact of EMR modification and a multi-disciplinary care team on the hepatitis C care cascade of a US Federally Qualified Health Center
EASL LiverTree™, Lora Magaldi, 206405
Human skin-derived precusor cells: a potential source for cellular therapy of the liver
EASL LiverTree™, Joery De Kock, 206941
Statin inhibits HDV assembly, secretion, and large hepatitis delta antigen-Smad3-Twist mediated epithelial-mesenchymal transition
EASL LiverTree™, Jaw-Ching Wu, 207683
Multidisciplinary intervention on lifestyle improves the management of patients with nonalcoholic fatty liver disease
EASL LiverTree™, Sara POLICARPO, 207795
Evaluation of the Xpert Fingerstick HCV Viral Load assay
EASL LiverTree™, François Lamoury, 206419
Liver biopsy derived induced pluripotent stem cells provide unlimited supply for the generation of hepatocyte-like cells.
EASL LiverTree™, Diego Calabrese, 206938
Molecular diversity of HDV strains that spread in France: a study of 2224 clinical strains prospectively collected during fifteen years
EASL LiverTree™, Athenaïs Gerber, 207711
Clinical Outcomes in biopsy-proven NAFLD Patients from the HEPAmet Spanish Registry.
EASL LiverTree™, Javier Ampuero, 207817
High agreement with HCV RNA in screening and DAA treatment monitoring indicates that cost-effective HCV core Ag test can also be enlisted in the fight to eliminate hepatitis C 
EASL LiverTree™, Nazibrola Chitadze, 206436
Differentiation of human pluripotent stem cells into hepatocytes is more efficient in spheroids than in 2D culture
EASL LiverTree™, Messina Antonietta, 206935
Cytokine-Dependent Activation of MAIT Cells by the TLR8 agonist GS-9688 but not the TLR7 Agonist GS-9620
EASL LiverTree™, Hassan Javanbakht, 207747
A mobile application for the management and follow-up of patients with Non-Alcoholic Fatty Liver Disease
EASL LiverTree™, Roberta Forlano, 207785
Eradicate Hepatitis C:  a pilot of treatment as prevention in active drug users
EASL LiverTree™, Jasmine Schulkind, 206389
Generation of a unique liver progenitor cell gene signature to identify LPCs and LPC activation in chronic liver diseases
EASL LiverTree™, Stefaan Verhulst, 206931
A novel chimpanzee adenoviral vectored HBV vaccine, encoding multiple HBV antigens with a shark invariant chain adjuvant, for use in HBV immunotherapy
EASL LiverTree™, Senthil Chinnakannan, 207725
NAFLD/NASH patients with compensated cirrhosis (CC) had a high prevalence of comorbidities, substantial liver disease progression, and increased annual number of hospitalizations and associated costs in France: a PMSI database analysis
EASL LiverTree™, Jérôme Boursier, 207788
Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with Sofosbuvir-based regimens
EASL LiverTree™, Alessandra Mangia, 210732
A phase 1/2, randomized, placebo controlled and open label extension studies of Givosiran and investigational RNA interference therapeutic, in patients with acute intermittent porphyria
EASL LiverTree™, Eliane Sardh, 210730
Award ceremony 2
EASL LiverTree™, Session Speakers, 210729
Primary spontaneous bacterial peritonitis prophylaxis is associated with greater ICU admission and 30-day mortality compared to secondary spontaneous bacterial peritonitis prophylaxis
EASL LiverTree™, Jasmohan S Bajaj, 210728
NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks
EASL LiverTree™, Stephen Harrison, 210727
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis c: the Navigator-II study
EASL LiverTree™, Roberta D'Ambrosio, 210726
The Impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients
EASL LiverTree™, Freya Wellhöner, 207346
Refinement of diagnostic criteria and frequency estimation of LPAC syndrome: a French multicenter study
EASL LiverTree™, Dong Catherine, 207363
Role of alpha-1 antitrypsin genotypes in the progression of adult liver disease
EASL LiverTree™, Vítor Magno Pereira, 207364
Mild iron overload in homozygous carriers of the alpha1-antitrypsin PiZ variant is not a major driver of liver fibrogenesis
EASL LiverTree™, Nurdan Guldiken, 207381
The ProC3 marker of type III collagen formation accurately reflects hepatic inflammation and fibrosis stage in asymptomatic alcoholic liver disease patients
EASL LiverTree™, Maja Thiele, 207399
Liver stiffness measurement predicts short-term liver related-morbidity of allogeneic hematopoietic stem cell transplantation
EASL LiverTree™, Thomas Karlas, 207401
Comparison of T2* and Signal Intensity Ratio Methods for MRI Assessment of Hepatic Iron Overload
EASL LiverTree™, Christopher Kagay, 207418
Serum biomarker usein decentralized care sites to overcome liver assessment barriers in patientswith chronic hepatitis C and HIV co-infection
EASL LiverTree™, anne loarec, 207419
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients
EASL LiverTree™, Elton Dajti, 207437
An effective defatting cocktail to reduce liver graft steatosis before transplantation
EASL LiverTree™, Lynda Aoudjehane, 207440
Chemokine receptor CXCR3 modulates polarization of tumor associated macrophages limiting tumor growth and angiogenesis in murine hepatocellular carcinoma
EASL LiverTree™, Elisa Fabiana Brandt, 207456
Hepatocyte-derived Osteopontin drives the development of hepatocellular carcinoma
EASL LiverTree™, Romain Desert, 207457
Activated platelets contribute to the progression of hepatocellular carcinoma by altering the immune cell environment
EASL LiverTree™, Natasa Pavlovic, 207474
Tumor-stroma crosstalk enhances Reg3A expressions that drives the progression of hepatocellular carcinoma 
EASL LiverTree™, Yuri Cho, 207476
 S100a11 is part of a whole network of tumor suppressors and oncogenes deregulatedearly with hepatic steatosis and contributing to hepatocellular carcinoma development
EASL LiverTree™, Cyril Sobolewski, 207493
Low density neutrophils, as immunosuppressant, increased in HCC patients, highly correlated with advanced stage, predicted stage I HCC recurrence and all patients survival
EASL LiverTree™, Chien-Hao Huang, 207494
Novel microRNA-based drug CD5-2 reduces liver cancer development in multi-drug-resistance gene-2 knockout mice
EASL LiverTree™, Ken Liu, 207511
KRAS-dependent AKT signaling drives hepatocyte proliferation to promote tumor development in a genetic model of liver cancer
EASL LiverTree™, Thomas Rösner, 207512
Sub maximally dilated Viatorr CX improves one year survival compared to conventional covered TIPS: a case-control study
EASL LiverTree™, Michael Praktiknjo, 207529
Prognosis after abdominal surgery in patients with idiopathic non-cirrhotic portal hypertension: a multicenter retrospective study
EASL LiverTree™, Laure ELKRIEF, 207530
Higher in-hospital and post-discharge mortality and hospital charges in cirrhotic patients with acute respiratory illness in the United States
EASL LiverTree™, Pauline Nguyen, 207545
Sepsis in HBV associated decompensated cirrhosis: A comparison between SIRS (Sepsis-1) and qSOFA (Sepsis-3) based criteria
EASL LiverTree™, Zhujun Cao, 207546
Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in cirrhosis: a systematic review and meta-analysis of randomized controlled trials
EASL LiverTree™, Roger F. Butterworth, 207561
Deleterious effect of proton pump inhibitors on the disease course of cirrhosis
EASL LiverTree™, Zsuzsanna Vitális, 207562
The prognosis following bacterascites is as poor as spontaneous bacterial peritonitis
EASL LiverTree™, Ji Jade King, 207579
MELD-score underestimates mortality in patients with nosocomial spontaneous bacterial peritonitis
EASL LiverTree™, Markus Kimmann, 207580
Improving assessment of hepatic encephalopathy in outpatient clinics 
EASL LiverTree™, Siddharth Sood, 207599
Liver cirrhosis and wound healing: Activation of von Willebrand factor and platelets
EASL LiverTree™, Lasse Langholm, 207615
The incidence of ulcer bleeding post endoscopic band ligation of esophageal varices
EASL LiverTree™, Salvador Machlab, 207616
the effect of new infection control measures for the prevention of hospital acquired infections in cirrhotic patients
EASL LiverTree™, Vincenza Di Gregorio, 207632
Presepsin, C reactive protein and procalcitonin have similar accuracy for bacterial infection and sepsis in decompensated cirrhosis 
EASL LiverTree™, Petra Fischer, 207633
Clinical impact, morbidity and mortality of Hepatitis E at tertiary referral centres in central Europe
EASL LiverTree™, Hartl Johannes, 207651
Dynamics of HBsAg clearance in a UK cohort of chronic HBV infection
EASL LiverTree™, Anna McNaughton, 207652
A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro
EASL LiverTree™, Lorenzo Piermatteo, 207670
Inhibition of Hepatitis Virus X protein (HBx) in HBV-Infected Primary Human Hepatocytes leads to the Reappearance of the Smc5/6 Complex
EASL LiverTree™, Rudolf Beran, 207686
FXR is a proviral factor whose binding to HBV genome is modulated by FXR agonist and correlates with presence of the activated chromatin mark H3K4me3 in an HBx dependant manner
EASL LiverTree™, Benoît Lacombe, 207687
Cellular RetinoicAcid-Binding Proteins Regulation of Hepatitis C Virus Infection
EASL LiverTree™, Takeshi Saito, 207703
Sodium taurocholate cotransporting popypeptide (NTCP) variants modulate HDV entry according to their function as a bile acid transporter but do not influence the antiviral effect of Myrcludex-B
EASL LiverTree™, Olympia Anastasiou, 207705
Estrogen receptor R1 and CAD are host factors for HDV replication and antiviral targets
EASL LiverTree™, Eloi VERRIER, 207721
Upregulated innate immune responses in a hepatitis C virus exposed uninfected cohort
EASL LiverTree™, Kristopher Bennett, 207742
Making sense of Liver Function tests: Is the Intelligent Liver Function Test (iLFT) cost-effective?
EASL LiverTree™, kathleen Boyd, 207760
Corticosteroid treatment is associated with a resolution of altered CD4+ T cell phenotype in patients with severe alcoholic hepatitis
EASL LiverTree™, Ashwin Dhanda, 207777
Risk factors for development of severe liver disease in more than 400 000 patients with type 2 diabetes: a population-based cohort study
EASL LiverTree™, Karl Björkström, 207794
Prevalence, severity and patterns of clinicalpractice in outpatient visits for suspected NAFLD - the German CONSTANS STUDY
EASL LiverTree™, Jörn Schattenberg, 207812
Role of L-carnitine in pathogenesis of the atherogenic dyslipidemia in ischemic heart disease with concominent nonalcoholic steatohepatitis
EASL LiverTree™, Igor Skrypnyk, 207829
Assessment of Baseline Hepatitis B Virus (HBV) Immunity and HBV Vaccine Responses in Prospectively Vaccinated Adults with Non Alcoholic Fatty Liver Disease (NAFLD)
EASL LiverTree™, Carla Coffin, 207830

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings